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Abstract 38 
Anti-Müllerian hormone (AMH) is required for sexual differentiation in the fetus, and in 39 
adult females AMH is produced by growing ovarian follicles. Consequently, AMH levels are 40 
correlated with ovarian reserve, declining towards menopause when the oocyte pool is 41 
exhausted. A previous genome-wide association study identified three genetic variants in and 42 
around the AMH gene that explained 25% of variation in AMH levels in adolescent males but 43 
did not identify any genetic associations reaching genome-wide significance in adolescent 44 
females. To explore the role of genetic variation in determining AMH levels in women of late 45 
reproductive age, we carried out a genome-wide meta-analysis in 3,344 pre-menopausal 46 
women from five cohorts (median age 44–48 years at blood draw). A single genetic variant, 47 
rs16991615, previously associated with age at menopause, reached genome-wide significance 48 
at P=3.48×10-10, with a per allele difference in age-adjusted inverse normal AMH of 0.26 SD 49 
(95% CI [0.18,0.34]). We investigated whether genetic determinants of female reproductive 50 
lifespan were more generally associated with pre-menopausal AMH levels. Genetically-51 
predicted age at menarche had no robust association but genetically-predicted age at 52 
menopause was associated with lower AMH levels by 0.18 SD (95% CI [0.14,0.21]) in age-53 
adjusted inverse normal AMH per one-year earlier age at menopause. Our findings provide 54 
genetic support for the well-established use of AMH as a marker of ovarian reserve. 55 
 56 
57 
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Introduction 58 
Anti-Müllerian hormone (AMH) is a member of the transforming growth factor-beta 59 
superfamily that regulates the growth and development of ovarian follicles in females and is 60 
required for sexual differentiation in the fetus, causing regression of the Müllerian ducts 61 
during testis development (1). In males, AMH is required for testes development and function 62 
and levels increase rapidly shortly after birth, peaking at 6 months of age, and then decline to 63 
low levels in during puberty (2). In women, AMH is produced by the granulosa cells of 64 
growing follicles and levels are correlated with the number of growing follicles and are used 65 
as a clinical measure of ovarian reserve (3). AMH levels increase in women from birth until 66 
their 20s, before declining gradually with age until levels are undetectable after menopause 67 
when ovarian reserve is exhausted (1, 3–6). Since AMH levels are stable throughout the 68 
menstrual cycle, they can be used as a measure of fertility in women of late reproductive age 69 
and to predict response to fertility treatment (7).  70 
AMH levels vary widely between women and genetic variation is thought to be important, 71 
though few genetic studies have been conducted. Rare AMH mutations have been found with 72 
functional effects on AMH signalling (8, 9), while polymorphisms in AMH or the gene 73 
coding for its receptor, AMHR2, have been associated with response to ovarian stimulation, 74 
infertility, follicle recruitment, primary ovarian insufficiency and polycystic ovary syndrome 75 
in candidate gene studies (10).  76 
A previous genome-wide association study (GWAS) in 1,360 adolescent males and 1,455 77 
adolescent females from a single cohort identified three genetic variants in and around the 78 
AMH gene that were independently associated with higher levels of AMH in adolescent 79 
males (P=2×10-49 to P=3×10-8 for each variant when jointly included in the regression model) 80 
(11). None of these variants showed strong evidence of statistical association in adolescent 81 
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females (P=8×10-4 to P=0.9 for each variant when jointly included in the regression model), 82 
with considerably weaker effect estimates than in males. For all three variants there was 83 
strong statistical evidence of a sex difference (PHET=3×10-4 to PHET=6×10-12), with the three 84 
cumulatively explaining 24.5% of the variation in AMH levels in males compared with 0.8% 85 
in females. No cohorts were available for replication of this initial study and it is unknown 86 
whether the weak or absent association in adolescent females persists into older ages, as 87 
would be expected since differences in ovarian decline result in variation in AMH levels 88 
between women. 89 
We undertook a GWAS meta-analysis of 3,344 women from five cohorts – the Generations 90 
Study, Sister Study, Nurses’ Health Study, Nurses’ Health Study II and Avon Longitudinal 91 
Study of Parents and Children (ALSPAC) − to investigate genetic determinants of AMH 92 
levels in pre-menopausal women of late reproductive age (median age at blood draw 44–48 93 
years). We aimed to identify novel genetic variants associated with AMH levels and to 94 
explore the effects of published genetic variants associated with AMH levels in previous 95 
GWAS and candidate gene studies.  96 
97 
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Results 98 
AMH is associated with a single significant signal in a known menopause locus 99 
In our genome-wide meta-analysis (Table 1), a single genetic variant in the MCM8 gene at 100 
20p12.3 reached genome-wide significance at P<5×10-8 (rs16991615, P=3.48×10-10) (Figure 101 
1,  Supplementary Figure 1). Within each of the five genotyped cohorts, we inverse-normally 102 
transformed AMH (to ensure normality of the residuals in the association analysis) and tested 103 
the association of over 11 million autosomal genetic variants imputed to HRC r1.1 2016 (12) 104 
adjusted for age and genetic relatedness (13). We performed inverse variance weighted meta-105 
analyses of the genome-wide results from the five cohorts, filtering our results to include only 106 
variants present in three or more of the five cohorts analysed, resulting in a total of 8.4 107 
million variants in the final results dataset (summary statistics to be made available through 108 
the EMBL-EBI GWAS catalogue at https://www.ebi.ac.uk/gwas/summary-statistics). A total 109 
of 242 variants had P<1×10-5, resulting in 24 signals following distance-based clumping of 110 
variants within 500kb, with the top ten signals presented in Table 2. The minor A allele of 111 
rs16991615 increased age-adjusted inverse normal AMH by 0.26 SD per allele (95% CI 112 
[0.18,0.34], P=3.48×10-10) (Table 2). 113 
 114 
Variants previously shown to be strongly associated with AMH levels in adolescent males 115 
had weak effects in pre-menopausal adult women in our study 116 
For three genetic variants in and around the AMH gene that were previously found to be 117 
independently associated with higher levels of AMH in adolescent males (11), we estimated 118 
the effects in pre-menopausal women when the variants were jointly included in the 119 
regression model (joint model), by carrying out approximate conditional analyses using the 120 
software GCTA (14). To allow comparison between our results and the original study’s 121 
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estimates, we generated effect estimates for age-adjusted inverse normal AMH in the 122 
adolescent males and females from the original study sample (ALSPAC offspring), since 123 
results from the original study were unadjusted and presented in natural log-transformed 124 
AMH.  125 
The effect estimates from the joint model for the three published genetic variants were 126 
directionally concordant across adolescent males and females (ALSPAC offspring cohort) 127 
and the pre-menopausal women in the current study (from five cohorts including ALSPAC 128 
mothers), but had about one-fifth of the effect on the level of AMH compared with the effect 129 
in adolescent males (PHET<0.001) (Figure 2). The weak or null effect sizes for rs4807216, 130 
rs8112524 and rs2385821 were similar in adolescent and pre-menopausal females (PHET>0.05 131 
for all). Genetic variant rs2385821 had the strongest effects in females of the three variants 132 
from the previous publication (11), but did not reach genome-wide significance in pre-133 
menopausal females (for joint model, per allele difference in age-adjusted inverse normal 134 
AMH of 0.27 SD (95% CI [0.13,0.41]), P=4.0×10-5) (Supplementary Table 1). 135 
 136 
Genetic variants for early menopause are associated with reduced levels of AMH  137 
Since the only genetic variant to reach genome-wide significance in our study (rs16991615) 138 
has previously been reported as associated with menopause timing (15–17), we investigated 139 
the association of AMH levels with all 56 genetic variants associated with menopause timing 140 
(17). The effect estimates of these genetic variants on AMH level were positively correlated 141 
with the published effects on age at menopause (r=0.83) and there were consistent directions 142 
of effect for 50/56 variants (P=1×10-9 for binomial sign test; χ256=194.39, P=4×10-17 for 143 
global chi-squared test of association) (Figure 3, Supplementary Table 2). There were no 144 
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obvious outliers among the 56 menopause timing variants and generally variants with large 145 
effects on age at menopause also had large effects on AMH levels.  146 
Two-sample Mendelian randomization analysis by inverse variance weighted (IVW) and 147 
Egger estimation supported a causal relationship between genetically-predicted age at 148 
menopause and pre-menopausal AMH level (Figure 3, Supplementary Table 2). For a one-149 
year increase in genetically-predicted age at menopause, age-adjusted inverse normal AMH 150 
was increased by 0.18 SD (95% CI [0.14,0.21]) with no horizontal pleiotropy detected by 151 
Egger analysis (in Egger analysis, 0.20 SD (95% CI [0.13,0.27]) age-adjusted inverse normal 152 
AMH per a one-year increase in genetically-predicted age at menopause one-year increase in 153 
genetically-predicted age at menopause, P-intercept=0.49). This relationship remained 154 
similar even when rs16991615 was excluded from the analysis (Supplementary Table 3). 155 
 156 
Genetic variants for age at menarche are not associated with AMH levels 157 
We investigated the effect of genetic variants associated with age at menarche on AMH 158 
levels (18), since menarche marks the start of cyclic selection of ovarian follicles from the 159 
growing follicle pool. We identified 327 of 389 published independent signals (18) in our 160 
meta-analysis results. For the 327 variants, there was little correlation between the published 161 
effect on age at menarche and the effect on AMH levels (r=-0.05) and the directions of 162 
effects were not consistent, with 158/327 (48%) in the same direction (P=0.58 for binomial 163 
sign test; χ2327=328.62, P=0.46 for global chi-squared test of association) (Figure 3, 164 
Supplementary Table 4). Two-sample Mendelian randomization analysis by IVW and Egger 165 
estimation found no causal relationship between age at menarche and AMH level (difference 166 
in mean age-adjusted inverse normal AMH per one-year increase in genetically-predicted age 167 
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at menopause was for IVW, -0.05 SD (95% CI [-0.12,0.02]) and for Egger, -0.03 SD (95% CI 168 
[-0.22,0.15], P-intercept=0.87) (Figure 3, Supplementary Table 3). 169 
 170 
Genetic variant for follicle-stimulating hormone levels is not associated with AMH levels 171 
Since levels of follicle-stimulating hormone (FSH) and luteinising hormone (LH) rise around 172 
menopause, we tested the association of a genetic variant at the FSHB locus that affects levels 173 
of these hormones (19) with AMH levels in pre-menopausal women. The FSHB promoter 174 
polymorphism (rs10835638; -211G>T) was not associated with AMH levels (per allele 175 
difference in age-adjusted inverse normal AMH of 0.01 SD (95% CI [-0.05,0.07]), P=0.79). 176 
 177 
Sensitivity analysis 178 
Results for genetic variants with P<5×10-5 in the main analysis were well-correlated whether 179 
we adjusted for age or not (r=0.99) (Supplementary Figure 2), used our favoured inverse 180 
normal transformation or a natural log transformation (as in reference (11)) (r=1.00) 181 
(Supplementary Figure 3), and when we excluded women whose AMH level was imputed as 182 
it was below the lower limit of detection (r=0.99) (Supplementary Figure 4). 183 
 184 
185 
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Discussion 186 
Our results indicate that variation in AMH levels in pre-menopausal women is contributed to 187 
by the underlying biology of ovarian reserve, as shown by the correlation between 188 
genetically-predicted age at menopause and AMH levels, supporting the use of AMH as a 189 
means of measuring ovarian reserve. The only signal passing genome-wide significance in 190 
our analyses was rs16991615 in MCM8, a published menopause timing variant (15–17), with 191 
the same allele associated with earlier menopause and lower AMH levels. Genome-wide 192 
analyses of menopause timing, a proxy measure for ovarian reserve, have identified 56 193 
genetic variants and highlighted the importance of DNA damage response pathways during 194 
follicle formation in utero and for follicle maintenance during a woman’s lifetime (17). 195 
Additionally, 389 genetic variants have been identified for menarche timing, the age at which 196 
cyclic selection of ovarian follicles from the pool of growing, AMH-producing follicles starts 197 
(18). Therefore, it is plausible that genetic determinants of menarche and menopause timing 198 
could affect ovarian reserve and influence AMH levels in pre-menopausal women, many 199 
years prior to menopause. For genetic variants associated with age at menopause, the 200 
published effect estimates were positively correlated with the effects on AMH levels and 201 
there was evidence of a causal relationship between genetically-predicted earlier menopause 202 
and lower pre-menopausal AMH levels, which remained even when rs16991615 was 203 
excluded. We did not find any association between genetically-predicted age at menarche and 204 
pre-menopausal AMH levels. We interpret these results as suggesting that AMH levels in 205 
pre-menopausal women are determined by declining ovarian reserve as a result of 206 
reproductive ageing but not menarche timing, and that women with lower AMH are nearer to 207 
the end of their reproductive lifespan.  208 
Variant rs16991615 has previously been found to be associated with differences in 209 
menopause timing by 0.9 years per allele and is a missense variant in exon 9 of MCM8 210 
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(E341K), which is required for homologous recombination (20). Other mutations in MCM8 211 
causing reduced double strand break repair have been found in women with premature 212 
ovarian failure (21) and follicle development is arrested at an early stage in MCM8 knockout 213 
mice (22). Pathway analysis has shown that the menopause timing variants identified from 214 
genome-wide analyses are enriched for genes involved in DNA damage response, including 215 
double-strand break repair during meiosis, suggesting that the genetic determinants of age at 216 
menopause act during ovarian follicle formation or maintenance, potentially affecting ovarian 217 
reserve from before birth until menopause (18). Therefore, it seems likely that rs16991615 218 
affects AMH levels through differences in ovarian reserve.  219 
Although the three published GWAS signals in and around the AMH gene (11) did not reach 220 
genome-wide significance when jointly included in the regression analysis, they did show 221 
directional consistency and were nominally associated in the pre-menopausal women in our 222 
study. The previous GWAS of adolescent females included fewer samples (n=1,455) than our 223 
analysis (n=3,344), hence we were better powered to detect the effects of these variants in 224 
females. The three published variants for AMH had smaller effects in pre-menopausal 225 
women compared with adolescent males but were consistent with the associations seen 226 
previously in adolescent females. The strongest signal in the GWAS of AMH levels in 227 
adolescents, rs4807216, was not associated with age at menopause in the most recent 228 
genome-wide meta-analysis (per allele difference in age-adjusted inverse normal AMH of 229 
0.05 SD (95% CI [-0.05, 0.15]), P=0.37) (17). Differences in genetic regulation of AMH 230 
levels in males and females are plausible given AMH’s different function in men and women. 231 
In males, AMH is required for regression of the Müllerian ducts during testis development in 232 
the fetus, and is involved in testicular development and function (2). In females, AMH is 233 
produced by granulosa cells of primary, pre-antral and small antral follicles, inhibiting both 234 
the further recruitment of primordial follicles from the follicle pool and also FSH-dependent 235 
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selection of follicles for growth during the menstrual cycle (3, 7, 23, 24). AMH expression 236 
starts in utero at 36 week’s gestation, peaking at around 25 years before declining to 237 
undetectable levels at menopause (3, 5, 7). In our analysis, a polymorphism in the promoter 238 
of FSHB (-211G>T) that affects FSH levels (25–27) had no effect on AMH levels in pre-239 
menopausal women, supporting the absence of direct negative feedback of FSH on AMH. 240 
AMH levels vary widely between women (6), reflecting factors such as variation in ovarian 241 
reserve, age and ethnicity (13). We controlled for age and ethnicity by adjusting for age and 242 
restricting our analyses to genetically European individuals. Adjustment for age will remove 243 
a source of variation in AMH level, the effect of the decrease in the primordial follicle pool 244 
with age, highlighting the effect of genetic variants responsible for variation in the initial size 245 
of the primordial follicle pool or that either accelerate or protect against loss of ovarian 246 
reserve with age. 247 
We would have been unable to detect low frequency variants or those with a smaller effect 248 
size since we were only powered (>80%) to detect a variant with a MAF of 5% and an effect 249 
of 0.36 SD or greater in the sample size analysed. We were unable to evaluate the effect of 250 
time from study participation to menopause on our results, to investigate whether the 251 
association of the menopause variants was modified by proximity to menopause, since we did 252 
not have sufficient follow-up data. Future analysis should consider stratifying by participants’ 253 
time to menopause. However, such analyses would require large numbers of women who had 254 
pre-menopausal AMH measurements (AMH levels are generally undetectable post-255 
menopause), recorded age at menopause and varying times of follow-up since age at 256 
menopause. We are not aware of any such study currently but with continued follow-up of 257 
the women included in this study such analyses may be possible. 258 
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This study confirms genetically that AMH levels are a marker for ovarian decline and 259 
reproductive ageing in pre-menopausal women. In addition to its use as a marker of fertility, 260 
there is evidence that AMH is a biomarker of breast cancer risk in pre-menopausal women. In 261 
a recent study, odds of pre- and postmenopausal breast cancer were 60% higher in women in 262 
the highest quartile of AMH level compared with the lowest, even after adjusting for 263 
potential confounders such as age (28). Our study suggests that these effects could be 264 
mediated through preserved ovarian reserve, or a correlate of ovarian reserve, as a result of 265 
delayed reproductive ageing, supported by findings from a large scale genomic analysis that 266 
showed a causal effect of later menopause on increased risk of breast cancer by 6% per year 267 
(17) and strong epidemiological evidence that later age at menopause increases risk of breast 268 
cancer (29). Our study provides genetic evidence that underlying biological factors 269 
responsible for reproductive ageing contribute to AMH levels in pre-menopausal women and 270 
are likely to be the main driver for the observed associations of AMH with health outcomes. 271 
 272 
 273 
274 
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Materials and Methods 275 
Studies included  276 
The central analysis team at University of Exeter Medical School coordinated data collection 277 
from the five studies. We included 3,344 women who had pre-menopausal AMH levels 278 
measured, who were participants in the Generations Study (30), the Sister Study (31), the 279 
Nurses’ Health Study, the Nurses’ Health Study II (32) and ALSPAC (33–35) (Table 1) 280 
(Supplementary Information). For the Generations Study, the Sister Study and the Nurses’ 281 
Health Studies, genotype and phenotype data were provided to the central analysis team for 282 
quality control, cleaning and analysis. For the ALSPAC study, quality control and genotype-283 
phenotype analyses were undertaken in house and summary descriptive, GWAS and 284 
sensitivity analyses statistics were provided to the central analysis team for meta-analysis.  285 
 286 
Genetic data 287 
In the Generations Study, Sisters and the Nurses’ Health Studies, samples were genotyped on 288 
the OncoArray array (Table 1). For the Nurses’ Health Studies, a further 225 samples were 289 
genotyped on an Illumina array. For each cohort and array type, data were cleaned using a 290 
standard quality control process in PLINK v1.9 (www.cog-genomics.org/plink/1.9/) (36). 291 
SNPs were removed if they were poorly genotyped (missing in >5% samples) or were not in 292 
Hardy-Weinberg equilibrium (P<1×10-6). Samples were removed if they were poorly 293 
genotyped (missing >5% SNPs), were a sex mismatch or were outliers in terms of 294 
heterozygosity. Within each cohort, samples that were related to each other as 3rd degree 295 
relatives or closer were identified and the sample with the greater proportion of missing SNPs 296 
was removed. Principal component analysis was carried out in FlashPCA in order to identify 297 
and remove genetically non-European samples from the analysis. SNPs with MAF>1% 298 
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aligned to the correct strand in HRC v1.1 were used for imputation. Genotypes for 299 
chromosomes 1–22 were phased using SHAPEIT and imputed to HRC r1.1 2016 using the 300 
University of Michigan Imputation Server (https://imputationserver.sph.umich.edu/) (12, 37, 301 
38).  302 
ALSPAC mothers were genotyped using the Illumina Human660W-Quad array at Centre 303 
National de Génotypage (CNG) and genotypes were called with Illumina GenomeStudio. 304 
Quality control was performed in PLINK v1.07 (39) by removing poorly genotyped SNPs 305 
(missing in >5% samples), not in Hardy-Weinberg equilibrium (P<1×10-6), or that had 306 
MAF<1%. Samples were removed if they were poorly genotyped (missing >5% SNPs), had 307 
indeterminate X chromosome heterozygosity or extreme autosomal heterozygosity. Samples 308 
showing evidence of population stratification were identified by multidimensional scaling of 309 
genome-wide identity by state (IBS) pairwise distances using the four HapMap populations 310 
as a reference, and then excluded (IBS>0.125). Haplotypes were estimated using SHAPEIT 311 
(v2.r644) (40) and phased haplotypes were then imputed to HRC panel (12) using IMPUTE 312 
V3. 313 
 314 
AMH phenotype 315 
For the Generations Study, Sister Study and the Nurses’ Health Studies, AMH levels were 316 
measured in blood samples taken from pre-menopausal women before breast cancer 317 
incidence by the individual studies as part of a collaborative, prospective study of AMH and 318 
breast cancer risk (28). Serum AMH levels were measured using an ultrasensitive ELISA 319 
(Ansh Labs, Webster, TX) (Sister Study) or a picoAMH enzyme-linked immunoabsorbent 320 
assay (Ansh Labs, Webster, TX) (Generations Study and the Nurses’ Health Studies, and 321 
samples below limit of detection of ELISA in Sister Study) (28). In ALSPAC, blood samples 322 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz015/5289469 by Institute of C
ancer R
esearch user on 28 January 2019
16 
 
were taken following a standardized protocol in women who attended a series of clinic 323 
assessments starting about 18 years after the index pregnancy and fasted (overnight or a 324 
minimum of 6 hours for those assessed in the afternoon) serum AMH levels were measured 325 
using the Beckman Coulter AMH Gen II ELISA assay (34, 35). 326 
For samples with AMH below the lower limit of detection, levels were imputed: for the 327 
Generations Study, the value was the midpoint between zero and the lower limit of detection 328 
(0.00821 pmol/L); for the Sister Study, missing values were imputed as 0.0015 ng/mL to be 329 
consistent with the previous analysis (28); for ALSPAC, measured AMH values <0.01 ng/mL 330 
were imputed to be 0.01 ng/mL. A small number of women (n=24) in the Nurses’ Health 331 
Studies with AMH below the lower limit of detection (2.038 pg/mL) were excluded from the 332 
analyses. For all studies, measured values of AMH were converted to pmol/L using 1 333 
pg/mL=0.00714 pmol/L and 1 ng/mL= 7.14 pmol/L. AMH was transformed by inverse 334 
normal transformation, in which the rank of the AMH value was converted to the z-score for 335 
the corresponding quantile of a standard normal distribution. This was done in order to 336 
approximate a normal distribution to ensure normality of the residuals in the association 337 
analysis and to rank the measured AMH values from each cohort to a consistent scale, 338 
avoiding the issue of consistently higher/lower AMH measurements due to the assay used. 339 
AMH levels for each study are summarised in Table 1. 340 
 341 
Genome-wide analysis 342 
Genome-wide linear regression analysis was carried separately for each of the five cohorts 343 
for autosomal genetic variants with imputation quality>0.4 assuming an additive model. Age 344 
at time the blood sample was taken was included as a covariate since age is known to be 345 
strongly associated with AMH levels and was negatively correlated with AMH level in 346 
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exploratory analysis (median age in each study is summarised in Table 1). For the 347 
Generations Study, Sisters and Nurses’ Health Study, analysis was carried out using 348 
GEMMA 0.94.1 (41), which calculates a genetic relationship matrix to account for cryptic 349 
relatedness and population stratification between the samples. The genetic relationship matrix 350 
was created from a pruned list of uncorrelated SNPs created in PLINK 1.9 (www.cog-351 
genomics.org/plink/1.9/) (36) using --indep-pairwise, excluding regions of long range linkage 352 
disequilibrium, based on variants with MAF>0.01, excluding variants with r2>0.5 (window 353 
size of 1000, calculated in steps of 50). The analysis included approximately 11.8 million 354 
genetic variants for the Generations Study, 12.9 million for the Sister Study, 12.3 million for 355 
Nurses’ Health Study OncoArray and 11.1 million for Nurses’ Health Study Illumina. For 356 
ALSPAC, the analysis was carried out in SNPTESTv2.5 (42) adjusting for the top ten 357 
principal components of ancestry which resulted in approximately 14.7 million SNPs.  358 
Standard error weighted meta-analysis of the individual GWAS results was carried out in 359 
METAL (version 2011-03-25) (43) with genomic control applied to account for inflation due 360 
to any remaining population stratification. Genetic variants included in the meta-analysis had 361 
imputation>0.4 and minor allele count>5 (calculated from allele frequencies), resulting in a 362 
total of 11.2 million autosomal SNPs that were analysed. Approximately 8.4 million variants 363 
were present in three or more of the five datasets analysed and were included in our final 364 
results. We identified independent signals as being suggestive of genome-wide association if 365 
they had P<1×10-5 and were more than 500kb from another signal; from these, we identified 366 
signals reaching genome-wide significance at P<5×10-8. 367 
Manhattan and quantile−quantile plots for the genome-wide association results were created 368 
using the package qqman (44) in R (The R Foundation for Statistical Computing). 369 
LocusZoom v1.4 (45) was used to plot the association statistics with age-adjusted inverse 370 
normal AMH for variants within 500kb of the top variant, showing linkage disequilibrium. 371 
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Linkage disequilibrium was calculated in PLINK v1.9 (www.cog-genomics.org/plink/1.9/) 372 
(36) from best guess genotypes for 1000 Genomes Phase 3/HRC imputed variants in 373 
~340,000 unrelated Europeans from the UK Biobank study (46). 374 
 375 
Generation of age-adjusted inverse normal effect estimates in ALSPAC offspring cohort 376 
For three published genetic variants that were associated with AMH levels in adolescent 377 
males in the ALSPAC offspring cohort (11), we generated effect estimates for age-adjusted 378 
inverse normal transformed AMH in the original study sample, since the original published 379 
estimates were unadjusted and presented in natural log-transformed AMH.  Analyses were 380 
carried in SNPTEST v2.5 (42) adjusting for the top ten principal components of ancestry and 381 
age and excluding the most extreme 1% of measured AMH values, resulting in 1,312 males 382 
and 1,421 females from the ALSPAC offspring cohort for analysis. Other methods were as 383 
described previously (11). 384 
 385 
Estimation of joint effects of variants in and around the AMH gene 386 
We used GCTA (version 1.25.0), using the command --cojo-joint (14), to carry out an 387 
approximate conditional analysis to estimate the joint effects of three genetic variants in and 388 
around the AMH gene (11). Linkage disequilibrium between the variants was estimated using 389 
a random sample of 8,569 white British individuals from the UK Biobank May 2015 interim 390 
release of imputed genetic data (47). 391 
 392 
Comparison of effects for published traits with AMH results 393 
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We compared the published effect estimates for 56 genetic variants associated with age at 394 
menopause (17) and 389 genetic variants associated with age at menarche (18) with their 395 
effects on AMH level in our analysis, by carrying out a Binomial sign test of directional 396 
consistency and calculating Pearson correlation coefficients.  To explore whether age at 397 
menopause or age at menarche causes differences in AMH levels, we used the genetic 398 
variants associated with menopause and menarche timing as instruments for age at 399 
menopause and age at menarche in two-sample Mendelian Randomization analyses. We used 400 
the Stata package mrrobust (48) to carry out inverse variance weighted (IVW) and Egger 401 
(which takes account of horizontal pleiotropy (49)) analyses. Analyses were carried out in 402 
Stata MP 13.0 and Stata SE 14.2 (StataCorp, TX, USA). 403 
 404 
Sensitivity analysis 405 
The genome-wide analysis was repeated without adjustment for age, using a natural log 406 
transformation (to be consistent with the previously published GWAS (11)), and also 407 
excluding women whose AMH level was imputed as it was below the lower limit of 408 
detection. We compared effect sizes in the main analysis with estimates from these alternate 409 
analyses for genetic variants with P<5×10-5 in the main analysis. 410 
 411 
  412 
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Legends to Figures 621 
Figure 1. Association statistics with age-adjusted inverse normal AMH for variants within 622 
500kb of rs16991615 (chr20:5948227) showing linkage disequilibrium with the top variant. 623 
Note: Linkage disequilibrium shown is in unrelated Europeans in UK Biobank. 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 634 
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/advance-article-abstract/doi/10.1093/hm
g/ddz015/5289469 by Institute of C
ancer R
esearch user on 28 January 2019
31 
 
Figure 2. Comparison of effect sizes of three genetic variants previously associated with 635 
higher levels of AMH (11) when jointly included in the regression model: effect in adolescent 636 
males and females from the ALSPAC offspring cohort (previous study, Perry et al 2016 (11)) 637 
and pre-menopausal women (current study). 638 
Note: Effect is difference in mean AMH per allele in standard deviations of age-adjusted 639 
inverse normal AMH. 640 
ES=effect size. 641 
 642 
 643 
 644 
 645 
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Figure 3. Inverse variance weighted and Egger two-sample Mendelian randomization 646 
analyses of the effect of genetically-predicted (a) age at menopause and (b) age at menarche 647 
on age-adjusted inverse normal AMH levels in pre-menopausal women.  648 
Note: Difference in mean age-adjusted inverse-normal AMH per one-year increase in 649 
genetically-predicted age at menarche or menopause. 650 
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Tables 653 
Table 1. AMH levels and age of women in each of the five cohorts included in the genome-654 
wide analysis.  655 
  Median (interquartile range) 
Study  n AMH (pmol/L) Age (years) at 
blood draw  
Generations Study 379 3.9 (0.8,11.7) 44 (40,48) 
Sister Study 438 1.2 (0.1,6.0) 48 (45,51) 
Nurses’ Health Studies 
(Illumina)1 
225 5.5 (1.5,12.4) 45 (42,48) 
Nurses’ Health Studies 
(OncoArray) 1 
417 6.7 (2.5,14.9) 44 (41,46) 
Avon Longitudinal Study of 
Parents and Children 
1,885 2.0 (0.4, 5.2) 46 (44,49) 
Total 3,344   
1Data from the Nurses’ Health Study and Nurses’ Health Study II were combined and 656 
genotyped on two different genome arrays, which were included as separate sub-samples in 657 
this analysis. 658 
 659 
Table 2. Top ten signals from the genome-wide analysis of age-adjusted inverse normal AMH 660 
in pre-menopausal women. 661 
SNPID Ch
r 
Pos EA/OA/E
AF 
Beta (SE) P-value Dir. Het. 
P 
Imp. 
qual 
rs169916
15 
20 5948227 A/G/0.06
8 
0.26 
(0.04) 
3.5×10-10 +++
++ 
0.14 0.94 
rs622368
81 
22 29450193 A/G/0.00
8 
0.85 
(0.16) 
1.1×10-7 +++
?? 
0.77 0.84 
rs186783
371 
5 88062223 T/A/0.01
1 
0.64 
(0.12) 
1.4×10-7 +++
+? 
0.64 0.61 
rs358293
51 
11 6120686 G/A/0.44
9 
0.11 
(0.02) 
2.7×10-7 +++
+- 
0.02 0.89 
rs107329
95 
1 17511157
4 
T/C/0.966 0.29 
(0.06) 
3.9×10-7 +++
++ 
0.86 0.93 
rs766733
57 
20 17831206 G/T/0.05
6 
0.22 
(0.04) 
5.0×10-7 +++
++ 
0.47 0.89 
rs716807
0 
15 93910220 T/C/0.329 0.11 
(0.02) 
5.5×10-7 +++
++ 
0.98 0.89 
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rs622376
17 
22 28761148 T/C/0.011 0.74 
(0.15) 
6.5×10-7 +++
?? 
0.89 0.82 
rs141456
816 
17 10362307 C/T/0.013 0.50 
(0.10) 
6.7×10-7 +++
+- 
0.44 0.66 
rs674376
1 
2 10393228 A/G/0.48
2 
0.09 
(0.02) 
2.7×10-6 +++
+- 
0.11 0.99 
 662 
Beta=difference in mean age-adjusted inverse normal AMH (SD) per allele. 663 
Chr=chromosome; Dir. = positive (+) or negative (-) direction of effect in Avon Longitudinal 664 
Study of Parents and Children, Sister Study, Generations Study, Nurses’ Health Studies 665 
(OncoArray), Nurses’ Health Studies (Illumina) respectively, with “?” indicating that the 666 
variant was absent; EA=effect allele; EAF=weighted average effect allele frequency across 667 
the studies; Het. P=P-value from Cochrane’s Q-test of heterogeneity of effects across the 668 
studies; Imp. qual = mean imputation quality across the studies; Pos=position in 669 
hg19/GRCh37; OA=other allele; SE=standard error. 670 
 671 
Abbreviations 672 
ALSPAC=Avon Longitudinal Study of Parents and Children 673 
AMH=anti-Müllerian hormone 674 
Chr=chromosome 675 
CI=confidence interval 676 
CNG=Centre National de Génotypage 677 
EA=effect allele 678 
EAF=weighted average effect allele frequency across the studies 679 
ES=effect size 680 
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FSH=follicle-stimulating hormone 681 
GWAS=genome-wide association study 682 
Het. P=P-value from Cochrane’s Q-test of heterogeneity of effects across the studies 683 
IBS=identity by state 684 
Imp. qual = mean imputation quality across the studies 685 
IVW=inverse variance weighted 686 
LH=luteinising hormone 687 
OA=other allele 688 
PCOS=polycystic ovary syndrome 689 
Pos=position in hg19/GRCh37 690 
SD=standard deviation 691 
SE=standard error 692 
 693 
Supplementary Information 694 
Details of studies included  695 
ALSPAC 696 
The ALSPAC study (34–36) is a prospective population-based birth cohort study that 697 
recruited 14,541 pregnant women resident in the South West of England with expected dates 698 
of delivery from 1st April 1991 to 31st December 1992 (http://www.alspac.bris.ac.uk.). The 699 
women and their offspring have been followed-up since that date and information presented 700 
here is from a subgroup of the original mothers who were pre-menopausal at the time of 701 
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AMH blood sampling (34–36). Ethical approval for the study was obtained from the 702 
ALSPAC Ethics and Law Committee and the Local Research Ethics Committees. Please note 703 
that the study website contains details of all the data that is available through a fully 704 
searchable data dictionary and variable search tool: 705 
http://www.bristol.ac.uk/alspac/researchers/our-data. 706 
Generations Study 707 
The Generations Study (31) is a prospective population cohort study started in 2003 to 708 
investigate the environmental, behavioural, hormonal and genetic causes of breast cancer 709 
(31). The cohort includes over 110 000 women aged 16 and older at entry, recruited from the 710 
general UK population through connections to the charity Breakthrough Breast Cancer (now 711 
Breast Cancer Now) or who volunteered as a result of publicity, and female friends and 712 
family members of participants. Follow-up questionnaires are mailed to participants about 713 
every 3 years. The study received appropriate ethical approval from the South East MREC, 714 
and informed consent was received from the participants. Detailed menstrual histories were 715 
collected and blood samples were contributed by 92% of participants.  716 
Nurses’ Health Study and Nurses’ Health Study II 717 
In 1976, 121,701 female, registered nurses, ages 30 to 55 years, were enrolled in the Nurses’ 718 
Health Study (33). Biennially, participants complete mailed questionnaires on lifestyle, diet, 719 
reproductive history, and disease diagnoses. In 1989–1990, 32,826 women ages 43 to 69 720 
years (21% premenopausal) donated blood samples.  721 
The Nurses’ Health Study II was established in 1989, when 116,430 female registered nurses, 722 
ages 25 to 42 years, completed and returned a questionnaire (33). The cohort has been 723 
followed biennially following the methods of the NHS. Between 1996 and 1999, 23,393 724 
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premenopausal participants, who were cancer-free and between the ages of 32 and 54 years, 725 
provided blood samples. 726 
Sister Study 727 
The Sister Study prospective cohort was designed to address genetic and environmental risk 728 
factors for breast cancer. During 2003-2009, 50,884 U.S. and Puerto Rican women ages 35-729 
74 were recruited through a national multi-media campaign and network of recruitment 730 
volunteers, breast cancer professionals and advocates. Eligible women had a sister who had 731 
been diagnosed with breast cancer but did not have breast cancer themselves. This research 732 
was approved by the Institutional Review Boards of the National Institute of Environmental 733 
Health Sciences, NIH, and the Copernicus Group. All participants provided informed 734 
consent. Data analysed in this study were from a subgroup of participants with a serum 735 
sample who were premenopausal (32). 736 
 737 
Supplementary Figure 1. (a) Manhattan and (b) QQ plot for GWAS of age-adjusted inverse 738 
normal AMH in pre-menopausal women.  739 
Supplementary Figure 2. Comparison of effect sizes in the main GWAS (SD of age-adjusted 740 
inverse normal AMH) and the analysis not adjusted for age (SD of inverse normal AMH) for 741 
genetic variants that were P<5×10-5 in the main GWAS. 742 
Supplementary Figure 3. Comparison of effect sizes in the main GWAS (SD of age-adjusted 743 
inverse normal AMH) and the natural log transformed analysis (SD of age-adjusted natural 744 
log transformed AMH) for genetic variants that were P<5×10-5 in the main GWAS. 745 
Supplementary Figure 4. Comparison of effect sizes in the main GWAS and the analysis 746 
excluding women with AMH measured as below the lower limit of detection (effects in SD 747 
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of age-adjusted inverse normal AMH for both) for genetic variants that were P<5×10-5 in the 748 
main GWAS. 749 
 750 
Supplementary Table 1. Comparison of effect sizes from univariate analyses and joint 751 
analyses (approximate conditional analyses in GCTA) in pre-menopausal women and 752 
adolescent males and females for three genetic variants associated with higher levels of AMH 753 
in adolescent males (10). 754 
Supplementary Table 2 Age-adjusted inverse normal AMH GWAS results and comparison of 755 
effect directions for 56 published age of menopause variants (Day et al 2015). 756 
Supplementary Table 3. Results of Mendelian Randomization analyses of the effect of 757 
genetically-predicted age at menopause and age at menarche on age-adjusted inverse normal 758 
AMH levels in pre-menopausal women. 759 
Supplementary Table 4 Age-adjusted inverse normal AMH GWAS results and comparison of 760 
effect directions for published age of menarche variants (Day et al 2017). 761 
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